TY - JOUR T1 - Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet’s disease JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2019-215437 SP - annrheumdis-2019-215437 AU - Giuseppe Lopalco AU - Vincenzo Venerito AU - Pietro Leccese AU - Giacomo Emmi AU - Luca Cantarini AU - Nancy Lascaro AU - Gerardo Di Scala AU - Claudia Fabiani AU - Donato Rigante AU - Florenzo Iannone Y1 - 2019/08/10 UR - http://ard.bmj.com/content/early/2019/08/10/annrheumdis-2019-215437.abstract N2 - Relapsing oral and genital ulcers (OGUs) represent the stigmata of Behçet’s disease (BD) and may be very painful, affecting both quality of life and relationships. A wide number of topical and immunosuppressive drugs can be used to treat ulcers,1 but failures are commonly reported. The efficacy of the phosphodiesterase-4 inhibitor apremilast has been proven in OGUs of BD in two randomised clinical trials (RCTs),2 3 whereas only two case reports are available until now.4 5 We aimed at evaluating the real-world effectiveness of apremilast in BD patients with OGUs refractory to conventional and/or biological treatments.We retrospectively evaluated patients classified as BD, according to International Criteria for BD6 and International Study Group7 criteria, who underwent apremilast (30 mg two times per day) for multirefractory OGUs from November 2017 to January 2019. The number of OGUs was assessed at baseline and either at 3 and 6 months. Pain from ulcers and BD activity were … ER -